Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients.

Dutzer, D

Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients. [electronic resource] - Alimentary pharmacology & therapeutics 06 2018 - 1571-1573 p. digital

Publication Type: Letter; Comment

1365-2036

10.1111/apt.14645 doi


Colitis, Ulcerative
Gastrointestinal Agents
Humans
Inflammatory Bowel Diseases
Infliximab
Point-of-Care Systems